Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hormones
Published in: Hormones 3/2018

01-09-2018 | Review Article

Endocrine paraneoplastic syndromes in lung cancer

Authors: Christoforos Efthymiou, Dionisios Spyratos, Theodore Kontakiotis

Published in: Hormones | Issue 3/2018

Login to get access

Abstract

Paraneoplastic syndromes are defined as a combination of clinical disorders associated with malignant diseases that are caused by the secretion of various substances by the tumor without, however, being caused by the direct growth and infiltration of the primary tumor, or due to the development of distant metastases. Despite the fact that lung cancer represents the number one cause of death from cancer worldwide, the new methods of treatment increase patient survival and the incidence of paraneoplastic syndromes. The most important ones of these are humoral hypercalcemia of malignancy, syndrome of inappropriate antidiuretic hormone, hyponatremia of malignancy, ectopic Cushing’s syndrome, carcinoid syndrome, and hypoglycemia and are usually a poor prognostic marker. Early diagnosis of those syndromes is achieved using specific criteria and may lead to early diagnosis of the underlying malignancy. It is essential to treat them with the overriding objective of improving the patients’ quality of life.
Literature
1.
Mazzone PJ, Arroliga AC (2003) Endocrine paraneoplastic syndromes in lung cancer. Curr Opin Pulm Med 9:313–320PubMedCrossRef
2.
3.
Spiro SG, Gould MK, Colice GL (2007) Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132:149S–160SPubMedCrossRef
4.
Carey VCI (1966) The Incidence of hypercalcemia in association with bronchogenic carcinoma. Am Rev Respir Dis 93:584–586PubMed
5.
Bender RA, Hansen H (1974) Hypercalcemia in bronchogenic carcinoma. A prospective study of 200 patients. Ann Intern Med 80:205–208PubMedCrossRef
6.
Hiraki A, Ueoka H, Bessho A et al (2002) Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer 95:1706–1713PubMedCrossRef
7.
Vassilopoulou-Sellin R, Newman BM, Taylor SH et al (1993) Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71:13091312
8.
Yoshimoto K, Yamasaki R, Sakai H et al (1989) Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 68:976–981PubMedCrossRef
9.
Nielsen PK, Rasmussen AK, Feldt-Rasmussen U et al (1996) Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab 81:3793–3796PubMed
10.
Lazaretti-Castro M, Kayath M, Jamnik S et al (1993) Prevalence of hypercalcemia in patients with lung cancer. Rev Assoc Med Bras 39:83–87PubMed
11.
Clines GA (2011) Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes 18:339–346PubMedCrossRef
12.
Jameson JL, Johnson BE (2008) Paraneoplastic syndromes: endrocrinologic/hematologic. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds) Harrison’s principles of internal medicine, 17th edn. McGraw Hill, Sudbury, pp 808–824
13.
Radulescu D, Pripon S, Bunea D, Ciuleanu TE, Radulescu LI (2007) Endocrine paraneoplastic syndromes in small cell lung carcinoma. Two case reports. J BUON 12:411–414PubMed
14.
Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373–379PubMedCrossRef
15.
16.
Ma XT, Yu LW, Fu J (2008) Paraneoplastic syndromes of hypercalcemia and leukocytosis associated with colonic metastases from squamous cell carcinoma of the lung. Int J Colorectal Dis 23:129–130PubMedCrossRef
17.
Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893–896PubMedCrossRef
18.
Hussain A, Adnan A, El-Hasani S (2012) Small cell carcinoma of the lung presented as acute pancreatitis. Case report and review of the literature. JOP 13:702–704PubMed
19.
Dolbey CH (2003) Hypercalcemia of malignancy. In: Wood ME, Philips GK (eds) Hematology/oncology secrets, 3rd edn. Hanley and Belfus, Philadelphia, pp 238–243
20.
Strewler GJ (2000) The physiology of parathyroid hormone-related protein. N Engl J Med 342:177–185PubMedCrossRef
21.
Takai E, Yano T, Iguchi H, Fukuyama Y, Yokoyama H, Asoh H, Ichinose Y (1996) Tumor-induced hypercalcemia and parathyroid hormone-related protein in lung carcinoma. Cancer 78:1384–1387PubMedCrossRef
22.
Coggeshall J, Merrill W, Hande K et al (1986) Implications of hypercalcemia with respect to diagnosis and treatment of lung cancer. Am J Med 80:325–328PubMedCrossRef
23.
Richerson MT (2004) Electrolyte imbalances. In: Yarbro CH, Frogge MH, Goodman M (eds) Cancer symptom management, 3rd edn. Jones and Bartlett, Sudbury, pp 440–460
24.
McClelland MT (2010) Paraneoplastic syndromes related to lung cancer. Clin J Oncol Nurs 14:357–364PubMedCrossRef
25.
Thomas L, Kwok Y, Edelman MJ (2004) Management of paraneoplastic syndromes in lung cancer. Curr Treat Options Oncol 5:51–62PubMedCrossRef
26.
McDonnell Keenan AMK, Wickham RS (2005) Hypercalcemia. In: Yarbro CH, Frogge MH, Goodman M (eds) Cancer nursing: principles and practice, 6th edn. Jones and Bartlett, Sudbury, pp 791–807
27.
Lorch G, Gilmore JL, Koltz PF, Gonterman RM, Laughner R, Lewis DA, Konger RL, Nadella KS, Toribio RE, Rosol TJ, Foley J (2007) Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. Br J Cancer 97:183–193PubMedPubMedCentralCrossRef
28.
LeGrand SB, Leskuski D, Zama I (2008) Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 149:259–263PubMedCrossRef
29.
Ricciardi S, de Marinis F (2009) Treatment of bone metastases in lung cancer: the actual role of zoledronic acid. Rev Recent Clin Trials 4:205–211PubMedCrossRef
30.
Potts JT Jr (2005) Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds) Harrison’s principles of internal medicine, 16th edn. Jones and Bartlett, Sudbury, pp 2249–2268
31.
32.
Silva OL, Becker KL (1973) Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med 132:337–339PubMedCrossRef
33.
Cvitkovic F, Armand JP, Tubiana-Hulin M et al (2006) Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 12:47–53PubMedCrossRef
34.
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139PubMedCrossRef
35.
Schwartz WB, Bennett W, Curelop S et al (1957) A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 23:529–542PubMedCrossRef
36.
Vorherr H, Massry SG, Utiger RD et al (1968) Antidiuretic principle in malignant tumor extracts from patients with inappropriate ADH syndrome. J Clin Endocrinol Metab 28:162–168PubMedCrossRef
37.
Amatruda TT, Mulrow PJ et al (1963) Carcinoma of the lung with inappropriate dieresis. Demonstration of an antidiuretic-like-hormone activity in tumor extract. N Engl J 269:544549CrossRef
38.
39.
Yeung SCJ et al (2011) Lung cancer-induced paraneoplastic syndromes. Curr Opin Pulm Med 17:260–268PubMedCrossRef
40.
Ost DE, Yeung SC, Tanoue LT, Gould MK (2013) Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e121S–e141SPubMedPubMedCentralCrossRef
41.
42.
Vanhees SL, Paridaens R, Vansteenkiste JF (2000) Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review. Ann Oncol 11:1061–1065PubMedCrossRef
43.
List AF, Hainsworth JD, Davis BW, Hande KR, Greco FA, Johnson DH (1986) The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 4:1191–1198PubMedCrossRef
44.
Hainsworth JD, Workman R, Greco FA (1983) Management of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. Cancer 51:161–165PubMedCrossRef
45.
Lokich JJ (1982) The frequency and clinical biology of the ectopic hormone syndromes of small cell carcinoma. Cancer 50:2111–2114PubMedCrossRef
46.
Monsieur I, Meysman M, Noppen M, de Greve J, Delhove O, Velckeniers B, Jacobvitz D, Vincken W (1995) Non-small-cell lung cancer with multiple paraneoplastic syndromes. Eur Respir J 8:1231–1234PubMedCrossRef
47.
Tho LM, Ferry DR (2005) Is the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in lung cancer always attributable to the small cell variety? Postgrad Med J 81:e17PubMedPubMedCentralCrossRef
48.
McDonald P, Lane C, Rojas GE, Masood A (2012) Syndrome of inappropriate anti-diuretic hormone in non-small cell lung carcinoma: a case report. Ecancermedicalscience 6:279PubMedPubMedCentral
49.
Praneet L, Mohammad I (2017) Syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) as an initial presenting sign of non small cell lung cancer-case report and literature review. Respir Med Case Rep 22:164e167
50.
Hansen O, Sorensen P, Hansen KH (2010) The occurrence of hyponatremia in SCLC and the influence on prognosis : a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 68:111–114PubMedCrossRef
51.
Kamoi K, Ebe T, Hasegawa A, Sato F, Takato H, Iwamoto H, Kaneko H, Ishibashi M, Yamaji T (1987) Hyponatremia in small cell lung cancer. Mechanisms not involving inappropriate ADH secretion. Cancer 60:1089–1093PubMedCrossRef
52.
Bliss DP, Battey JF, Linnoila RI, Birrer MJ, Gazdar AF, Johnson BE (1990) Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst 82:305–310PubMedCrossRef
53.
Campling BG, Sarda IR, Baer KA, Pang SC, Baker HM, Lofters WS, Flynn TG (1995) Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer 75:2442–2451PubMedCrossRef
54.
Gandhi L, Johnson B (2006) Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Cancer Netw 4:631–638CrossRef
55.
Cogan E, Debiève MF, Philipart I, Pepersack T, Abramow M (1986) High plasma levels of atrial natriuretic factor in SIADH. N Engl J Med 314:1258–1259PubMedCrossRef
56.
Donckier JE, Meunier HT, Ketelslegers JM, Lambert AE (1986) Atrial natriuretic peptide and the syndrome of inappropriate secretion of antidiuretic hormone. Ann Intern Med 105:795–796PubMedCrossRef
57.
Armstrong TS (2005) Paraneoplastic syndromes. In: Yarbro CH, Frogge MH, Goodman M (eds) Cancer nursing: principles and practice, 6th edn. Jones and Bartlett, Sudbury, pp 808–824
58.
Saintigny P, Chouahnia K, Cohen R, Pailler MC, Brechot JM, Morere JF, Breau JL (2007) Tumor lysis associated with sudden onset of syndrome of inappropriate antidiuretic hormone secretion. Clin Lung Cancer 8:282–284PubMedCrossRef
59.
Raftopoulos H (2007) Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer 15:1341–1347PubMedCrossRef
60.
Vaidya C, Ho W, Freda BJ (2010) Management of hyponatremia: providing treatment and avoiding harm. Cleve Clin J Med 77:715–726PubMedCrossRef
61.
Demeclocycline DTA (1977) Treatment for syndrome of inappropriate antidiuretic hormone secretion. JAMA 237:2723–2726CrossRef
62.
Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A (1998) Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 357:63–69PubMedCrossRef
63.
Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T (2007) Tolvaptan, an orally active vasopressin V(2)-receptor antagonist—pharmacology and clinical trials. Cardiovasc Drug Rev 25:1–13PubMedCrossRef
64.
Kenz S, Haas CS, Werth SC, Bohnet S, Brabant G (2011) High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH). Ann Oncol 22:2696PubMedCrossRef
65.
Meador CK, Liddle GW, Island DP et al (1962) Cause of Cushing’s syndrome in patients with tumors arising from ‘nonendocrine’ tissue. J Clin Endocrinol Metab 22:693–703PubMedCrossRef
66.
Auchus RJ, Mastorakos G, Friedman TC, Chrousos GP (1994) Corticotropin-releasing hormone production by a small cell carcinoma in a patient with ACTH-dependent Cushing’s syndrome. J Endocrinol Invest 17:447–452PubMedCrossRef
67.
Shahani S, Nudelman RJ, Nalini R, Kim HS, Samson SL (2010) Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature. Diagn Pathol 5:56PubMedPubMedCentralCrossRef
68.
69.
Oldfield EH, Doppman JL, Nieman LK et al (1991) Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome. N Engl J Med 325:897–905PubMedCrossRef
70.
Wajchenberg BL, Mendonca B, Liberman B et al (1995) Ectopic ACTH syndrome. J Steroid Biochem Mol Biol 53:139–151PubMedCrossRef
71.
Howlett TA, Drury PL, Perry L et al (1986) Diagnosis and management of ACTH-dependent Cushing’s syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf) 24:699–713CrossRef
72.
De Graaf M, de Beukelaar J, Bergsma J et al (2008) B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. J Neuroimmunol 195:164–170PubMedCrossRef
73.
Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F (1992) Cushing’s syndrome associated with ectopic corticotrophin production and small-cell lung cancer. J Clin Oncol 10:21–27PubMedCrossRef
74.
Delisle L, Boyer MJ, Warr D, Killinger D, Payne D, Yeoh JL, Feld R (1993) Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med 153:746–752PubMedCrossRef
75.
Morandi U, Casali C, Rossi G (2006) Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg 18:191–198PubMedCrossRef
76.
Barbosa SL, Rodien P, Leboulleux S, Niccoli-Sire P, Kraimps JL, Caron P, Archambeaud-Mouveroux F, Conte-Devolx B, Rohmer V (2005) Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid 15:618–623PubMedCrossRef
77.
Sarid N, Osher E, Gat A, Hoffman M, Oster HS (2012) Cushing’s syndrome as a harbinger of relapsed nonsmall cell lung cancer. Isr Med Assoc J 14:523–524PubMed
78.
Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, Zwimpfer C, Figge AM, Flyvbjerg A, Lankisch PG, Blum WF, Klöppel G, Schmiegel W, Zapf J (2007) Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab 92:1600–1605PubMedCrossRef
79.
Dimopoulos MA, Fernandez JF, Samaan NA et al (1992) Paraneoplastic Cushing’s syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer 69:66–71PubMedCrossRef
80.
Sarlis NJ, Chanock SJ, Nieman LK (2000) Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 85:42–47PubMed
81.
Small M, Lowe GD, Forbes CD et al (1983) Thromboembolic complications in Cushing’s syndrome. Clin Endocrinol (Oxf) 19:503–511CrossRef
82.
Kastelan D, Dusek T, Kraljevic I et al (2009) Hypercoagulability in Cushing’s syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 36:70–74PubMedCrossRef
83.
Van Zaane B, Nur E, Squizzato A et al (2009) Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab 94:2743–2750PubMedCrossRef
84.
Guignat L, Bertherat J (2010) The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. Eur J Endocrinol 163:9–13PubMedCrossRef
85.
Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526–1540PubMedPubMedCentralCrossRef
86.
Flack MR, Oldfield EH, Cutler GB, Zweig MH, Malley JD, Chrousos GP, Loriaux DL, Nieman LK (1992) Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Ann Intern Med 116:211–217PubMedCrossRef
87.
Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19:647–672PubMed
88.
Kaye TB, Crapo L (1990) The Cushing syndrome: an update on diagnostic tests. Ann Intern Med 112:434–444PubMedCrossRef
89.
Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F (1999) Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84:440–448PubMed
90.
91.
Torpy DJ, Chen CC, Mullen N, Doppman JL, Carrasquillo JA, Chrousos GP, Nieman LK (1999) Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 84:1186–1192PubMedCrossRef
92.
Collichio FA, Woolf PD, Brower M (1994) Management of patients with small cell carcinoma and the syndrome of ectopic corticotropin secretion. Cancer 73:1361–1367PubMedCrossRef
93.
Gustafsson BI, Kidd M, Chan A et al (2008) Bronchopulmonary neuroendocrine tumors. Cancer 113:5–21PubMedCrossRef
94.
Beasley MB, Brambilla E, Travis WD (2005) The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 40:90–97PubMedCrossRef
95.
Lim E, Goldstraw P, Nicholson AG et al (2008) Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol 3:1194–1201PubMedCrossRef
96.
Seregni E, Ferrari L, Bajetta E et al (2001) Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 12(Suppl 2):S69–S72PubMedCrossRef
97.
Kvols LK (1989) Therapy of the malignant carcinoid syndrome. Endocrinol Metab Clin North Am 18:557–568PubMedCrossRef
98.
99.
Ahmadieh H, Arabi A (2015) Endocrine paraneoplastic syndromes: a review. Endocrinol Metab Int J 1(1):00004
100.
Faglia G, Arosio M, Bazzoni N (1992) Ectopic acromegaly. Endocrinol Metab Clin N Am 21:575–595CrossRef
101.
Biswal S, Srinivasan B, Dutta P, Ranjan P, Vaiphei K, Singh RS, Thingnam SS (2008) Acromegaly caused by ectopic growth hormone: a rare manifestation of a bronchial carcinoid. Ann Thorac Surg 85:330–332PubMedCrossRef
102.
Metz SA, Weintraub B, Rosen SW et al (1978) Ectopic secretion of chorionic gonadotropin by a lung carcinoma. Pituitary gonadotropin and subunit secretion and prolonged chemotherapeutic remission. Am J Med 65:325–333PubMedCrossRef
103.
Hunstein W, Trumper LH, Dummer R et al (1988) Glucagonoma syndrome and bronchial carcinoma. Ann Intern Med 109:920–921PubMedCrossRef
104.
Hocqueloux L, Mortier E, Cabane J (1998) Pseudopheochromocytoma : an unrecognized cancer-associated syndrome. Arch Intern Med 158:1381–1382PubMedCrossRef
105.
Abou-saif A, Lei J, McDonald TJ et al (2001) A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer. Gastroenterology 120:1271–1278PubMedCrossRef
Metadata
Title
Endocrine paraneoplastic syndromes in lung cancer
Authors
Christoforos Efthymiou
Dionisios Spyratos
Theodore Kontakiotis
Publication date
01-09-2018
Publisher
Springer International Publishing
Published in
Hormones / Issue 3/2018
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI
https://doi.org/10.1007/s42000-018-0046-0

Other articles of this Issue 3/2018

Hormones 3/2018 Go to the issue

Case Report

Presentation of central precocious puberty in two patients with Tay-Sachs disease

Original Article

Significant effect of group education in patients with diabetes type 1

Original Article

Brain activation during repeated imagining of chocolate consumption: a functional magnetic resonance imaging study

Case Report

Heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A1) can cause transient adrenal insufficiency and life-threatening failure to thrive

Original Article

The effectiveness of a health promotion and stress-management intervention program in a sample of obese children and adolescents

Original Article

Management of acromegaly: an exploratory survey of physicians from the Middle East and North Africa
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits